Home LiteratureArticle Details
PMID: 15550200 Published · ppublish English Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Evaluating human papillomavirus vaccination programs.

Emerging infectious diseases ·Vol. 10 ·No. 11 ·2004-11-00 ·Pages 1915-23

Taira AV, Neukermans CP, Sanders GD

Abstract

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated HPV prevalence and infection rates for the population overall, by age group, by level of sexual activity within each age group, and by sex. Data were based on clinical trials and published and unpublished sources. An HPV-16/18 vaccine for 12-year-old girls would reduce cohort cervical cancer cases by 61.8%, with a cost-effectiveness ratio of 14,583 dollars per quality-adjusted life year (QALY). Including male participants in a vaccine rollout would further reduce cervical cancer cases by 2.2% at an incremental cost-effectiveness ratio of 442,039 dollars/QALY compared to female-only vaccination. Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination.

MeSH Terms
Adolescent Adult Age Factors Female Humans Immunization Schedule Male Middle Aged Papillomavirus Infections/prevention & control Sex Factors Uterine Cervical Neoplasms/prevention & control Vaccination/economics Viral Vaccines
Chemicals
Viral Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Taira Al V
Stanford School of Medicine, Stanford, California, USA.
Neukermans Christopher P
Sanders Gillian D
References (34)
34 references, click to expand
  1. HPV vaccines for cervical cancer move toward clinic, encounter social issues.
    J Natl Cancer Inst. 1997 Nov 19;89(22):1664-6 PMID: 9390534
  2. Mathematical models of disease transmission: a precious tool for the study of sexually transmitted diseases.
    Can J Public Health. 1997 Jul-Aug;88(4):255-65 PMID: 9336095
  3. Private sexual behavior, public opinion, and public health policy related to sexually transmitted diseases: a US-British comparison.
    Am J Public Health. 1998 May;88(5):749-54 PMID: 9585739
  4. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing.
    JAMA. 1999 Jan 27;281(4):347-53 PMID: 9929088
  5. Estimates of the worldwide incidence of 25 major cancers in 1990.
    Int J Cancer. 1999 Mar 15;80(6):827-41 PMID: 10074914
  6. Estimates of the worldwide mortality from 25 cancers in 1990.
    Int J Cancer. 1999 Sep 24;83(1):18-29 PMID: 10449602
  7. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.
    Stat Med. 1999 Dec 15;18(23):3263-82 PMID: 10602150
  8. Human papillomavirus vaccines.
    Semin Cancer Biol. 1999 Dec;9(6):431-44 PMID: 10712890
  9. Acceptability of human papillomavirus immunization.
    J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):47-50 PMID: 10718505
  10. Comparative epidemiology of heterosexual gonococcal and chlamydial networks: implications for transmission patterns.
    Sex Transm Dis. 2000 Apr;27(4):215-23 PMID: 10782743
  11. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types.
    Int J Cancer. 2000 Jul 15;87(2):221-7 PMID: 10861478
  12. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.
    Am J Epidemiol. 2000 Jun 15;151(12):1158-71 PMID: 10905528
  13. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies.
    J Clin Virol. 2000 Oct;19(1-2):25-30 PMID: 11091145
  14. Public health paradoxes and the epidemiological impact of an HPV vaccine.
    J Clin Virol. 2000 Oct;19(1-2):101-11 PMID: 11091153
  15. Papillomavirus-like particle vaccines.
    J Natl Cancer Inst Monogr. 2001;(28):50-4 PMID: 11158207
  16. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina.
    Arch Pediatr Adolesc Med. 2001 Apr;155(4):455-61 PMID: 11296072
  17. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
    JAMA. 2001 Jun 27;285(24):3107-15 PMID: 11427139
  18. The theoretical population-level impact of a prophylactic human papilloma virus vaccine.
    Epidemiology. 2002 Nov;13(6):631-9 PMID: 12410003
  19. A controlled trial of a human papillomavirus type 16 vaccine.
    N Engl J Med. 2002 Nov 21;347(21):1645-51 PMID: 12444178
  20. Cost-effectiveness of a potential vaccine for human papillomavirus.
    Emerg Infect Dis. 2003 Jan;9(1):37-48 PMID: 12533280
  21. Economic evaluation of vaccination programs: the impact of herd-immunity.
    Med Decis Making. 2003 Jan-Feb;23(1):76-82 PMID: 12583457
  22. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
    JAMA. 2003 Aug 13;290(6):781-9 PMID: 12915431
  23. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    J Natl Cancer Inst. 2004 Apr 21;96(8):604-15 PMID: 15100338
  24. The geography of gonorrhea. Empirical demonstration of core group transmission.
    Am J Epidemiol. 1983 Jun;117(6):688-94 PMID: 6859024
  25. Differences in rates of cancer screening by usual source of medical care. Data from the 1987 National Health Interview Survey.
    Med Care. 1991 Mar;29(3):196-209 PMID: 1997750
  26. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.
    N Engl J Med. 1992 Oct 29;327(18):1272-8 PMID: 1328880
  27. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent.
    Int J Cancer. 1993 Apr 1;53(6):919-23 PMID: 8386137
  28. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon.
    Sex Transm Dis. 1993 Sep-Oct;20(5):274-8 PMID: 8235925
  29. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C.
    Sex Transm Dis. 1993 Sep-Oct;20(5):279-85 PMID: 8235926
  30. Persistence of type-specific human papillomavirus infection among cytologically normal women.
    J Infect Dis. 1994 Feb;169(2):235-40 PMID: 8106758
  31. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
    J Pathol. 1999 Sep;189(1):12-9 PMID: 10451482
  32. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.
    J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 PMID: 7791229
  33. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.
    J Epidemiol Community Health. 1995 Jun;49(3):238-44 PMID: 7629457
  34. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.
    J Pediatr. 1998 Feb;132(2):277-84 PMID: 9506641
Article Info
Journal
Emerging infectious diseases
Abbr.
Emerg Infect Dis
ISSN
1080-6040
DOI
10.3201/eid1011.040222
Published
2004-11-00
Pages
1915-23
Language
English
Region
United States
NLM ID
9508155
PMCID
PMC3328990
Subset
IM
External Links
PubMed source DOI: 10.3201/eid1011.040222 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2